NeXT Personal for Ultra-sensitive MRD Detection & Response Monitoring
Time: 12:00 pm
day: Day One
Details:
- Tumor-informed whole genome sequencing based technology with superior sensitivity and high specificity
- Clinical Evidence from TRACERx demonstrating the applicability of NeXT Personal in early stage lung cancer
- How ultra-sensitivity matters and is clinically meaningful
